Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Phase 2

Recruiting

Conditions: Melanoma
Melanoma Stage III

Interventions: Diagnostic Test: PET Scan
Drug: Nivolumab
Drug: Ipilimumab
Procedure: Surgical Resection of Melanoma

First Posted Date: 2022-03-21

Last Posted Date: 2024-04-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT05289193

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

and more 1 locations

Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Phase 2

Recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2022-02-02

Last Posted Date: 2023-11-21

Lead Sponsor: Spanish Oncology Genito-Urinary Group

Target Recruit Count: 66

Registration Number: NCT05219435

Locations: 🇪🇸
Hospital Universitario de Toledo, Toledo, Castilla La Mancha, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Comunidad Autónoma De Madrid, Spain
🇪🇸
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain

and more 9 locations

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Phase 2

Active, not recruiting

Conditions: Renal Cancer Metastatic

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2022-01-31

Last Posted Date: 2024-07-03

Lead Sponsor: Hospital das Clínicas de Ribeirão Preto

Target Recruit Count: 100

Registration Number: NCT05215470

Locations: 🇧🇷
Hospital das Clínicas da Faculdade de Medicina de Ribeirao Preto - USP, Ribeirão Preto, Sao Paulo, Brazil

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2

Completed

Conditions: Refractory Cutaneous Melanoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Cabozantinib

First Posted Date: 2022-01-20

Last Posted Date: 2024-07-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 4

Registration Number: NCT05200143

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Early Phase 1

Recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Cabozantinib
Drug: Ipilimumab
Drug: Nivolumab
Drug: Lenvatinib
Drug: Everolimus

First Posted Date: 2022-01-12

Last Posted Date: 2024-11-06

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT05188118

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer
Metastatic Castration-resistant Prostate Cancer
Colorectal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Solid Tumor

Interventions: Drug: Zanzalintinib
Drug: Ipilimumab
Drug: Nivolumab
Drug: Nivolumab + Relatlimab

First Posted Date: 2022-01-04

Last Posted Date: 2024-10-18

Lead Sponsor: Exelixis

Target Recruit Count: 1274

Registration Number: NCT05176483

Locations: 🇺🇸
Exelixis Clinical Site #32, Pittsburgh, Pennsylvania, United States
🇺🇸
Exelixis Clinical Site #24, Pittsburgh, Pennsylvania, United States
🇺🇸
Exelixis Clinical Site #89, Dallas, Texas, United States

and more 119 locations

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Phase 1

Completed

Conditions: Melanoma, Cutaneous
Metastatic Melanoma
Melanoma, Mucosal
Melanoma, Ocular
Liver Metastases

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Procedure: Stereotactic Body Radiation Therapy

First Posted Date: 2021-12-27

Last Posted Date: 2024-11-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 2

Registration Number: NCT05169957

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Phase 2

Active, not recruiting

Conditions: Prostatic Neoplasms
Prostate Cancer
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Disease
Genital Neoplasms, Male

Interventions: Drug: 177Lu-PSMA-617
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2021-12-09

Last Posted Date: 2023-12-15

Lead Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Target Recruit Count: 93

Registration Number: NCT05150236

Locations: 🇦🇺
Royal Brisbane and Womens hospital, Herston, Queensland, Australia
🇦🇺
Sir Charles Gairdner, Nedlands, Western Australia, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 5 locations

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Phase 2

Recruiting

Conditions: Lung Cancer Metastatic

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Evolocumab

First Posted Date: 2021-12-03

Last Posted Date: 2024-07-18

Lead Sponsor: Scott Antonia

Target Recruit Count: 38

Registration Number: NCT05144529

Locations: 🇺🇸
Duke Univ. Medical Center, Durham, North Carolina, United States

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 3

Active, not recruiting

Conditions: Gastric Cancer

Interventions: Drug: ONO-4538
Drug: Oxaliplatin
Drug: Ipilimumab
Drug: Capecitabine
Drug: S-1

First Posted Date: 2021-12-03

Last Posted Date: 2024-07-31

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 626

Registration Number: NCT05144854

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇯🇵
IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan

and more 54 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy